Last reviewed · How we verify
AbobotulinumtoxinA dose 1
AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscles to reduce muscle spasms and improve muscle tone.
AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscles to reduce muscle spasms and improve muscle tone. Used for Glabellar lines, Frown lines, Crows feet.
At a glance
| Generic name | AbobotulinumtoxinA dose 1 |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Botulinum toxin |
| Target | Acetylcholine receptor |
| Modality | Biologic |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It does this by blocking the release of acetylcholine, a neurotransmitter that stimulates muscle contraction. This results in a reduction in muscle spasms and an improvement in muscle tone. The effects are typically temporary and reversible.
Approved indications
- Glabellar lines
- Frown lines
- Crows feet
Common side effects
- Eyelid ptosis
- Eyelid drooping
- Headache
- Dry eye
- Eye irritation
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy (PHASE4)
- Comparison of Dry Needling and Two Botulinum Toxins for Bruxism (NA)
- Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity (PHASE4)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (PHASE3)
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (PHASE1, PHASE2)
- A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AbobotulinumtoxinA dose 1 CI brief — competitive landscape report
- AbobotulinumtoxinA dose 1 updates RSS · CI watch RSS
- Galderma R&D portfolio CI